Another genetic testing company? Why a different approach could boost drug predictions and R&D.
Even after declaring bankruptcy, 23andMe sat on a treasure trove of personal genetic data from millions of people when it announced that Regeneron would be acquiring it earlier this year. But ultimately, that coveted data was the reason the deal fell …